Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Clinical & Experimental Metastasis
Published in: Clinical & Experimental Metastasis 1/2014

01-01-2014 | Research Paper

Class III β-tubulin overexpression within the tumor microenvironment is a prognostic biomarker for poor overall survival in ovarian cancer patients treated with neoadjuvant carboplatin/paclitaxel

Authors: Dana M. Roque, Natalia Buza, Michelle Glasgow, Stefania Bellone, Ileana Bortolomai, Sara Gasparrini, Emiliano Cocco, Elena Ratner, Dan-Arin Silasi, Masoud Azodi, Thomas J. Rutherford, Peter E. Schwartz, Alessandro D. Santin

Published in: Clinical & Experimental Metastasis | Issue 1/2014

Login to get access

Abstract

Critics have suggested that neoadjuvant chemotherapy (NACT) followed by interval debulking may select for resistant clones or cancer stem cells when compared to primary cytoreduction. β-tubulins are chemotherapeutic targets of taxanes and epothilones. Class III β-tubulin overexpression has been linked to chemoresistance and hypoxia. Herein, we describe changes in class III β-tubulin in patients with advanced ovarian carcinoma in response to NACT, in relationship to clinical outcome, and between patients who underwent NACT versus primary debulking; we characterize in vitro chemosensitivity to paclitaxel/patupilone of cell lines established from this patient population, and class III β-tubulin expression following repeated exposure to paclitaxel. Using immunohistochemistry, we observed among 22 paired specimens obtained before/after NACT decreased expression of class III β-tubulin following therapy within stroma (p = 0.07), but not tumor (p = 0.63). Poor median overall survival was predicted by high levels of class III β-tubulin in both tumor (HR 3.66 [1.11,12.05], p = 0.03) and stroma (HR 4.53 [1.28,16.1], p = 0.02). Class III β-tubulin expression by quantitative-real-time-polymerase-chain-reaction was higher among patients who received NACT (n = 12) compared to primary cytoreduction (n = 14) (mean ± SD fold-change: 491.2 ± 115.9 vs. 224.1 ± 55.66, p = 0.037). In vitro subculture with paclitaxel resulted in class III β-tubulin upregulation, however, cell lines that overexpressed class III β-tubulin remained sensitive to patupilone. Overexpression of class III β-tubulin in patients dispositioned to NACT may thus identify an intrinsically aggressive phenotype, and predict poor overall survival and paclitaxel resistance. Decreases in stromal expression may represent normalization of the tumor microenvironment following therapy. Epothilones warrant study for patients who have received neoadjuvant carboplatin and paclitaxel.
Literature
1.
Vergote I, Tropé CG, Amant F, Kristensen GB, Ehlen T, Johnson N, Verheijen RHM, van der Burg MEL, Lacave AJ, Benedetti-Panici P, Kenter GG, Casado A, Mendiola C, Coens C, Verleye L, Stuart GC, Pecorelli S, Reed NS (2010) Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. New Engl J Med 363:943–953PubMedCrossRef
2.
Kang S, Nam BH (2009) Does neoadjuvant chemotherapy increase optimal cytoreduction rate in advanced ovarian cancer? Meta-analysis of 21 studies. Ann Surg Oncol 16:2315–2320PubMedCrossRef
3.
Crawford SC, Vasey PA, Paul J, Hay A, Kaye SB (2005) Does aggressive surgery only benefit patients with less advanced cancer? Results from an international comparison within the SCOTROC-1 Trial. J Clin Oncol 23:8802–8811PubMedCrossRef
4.
Glasgow MA, Yu H, Rutherford TJ, Azodi M, Silasi DA, Santin AD, Schwartz PE (2013) Neoadjuvant chemotherapy (NACT) is an effective way of managing elderly women with advanced stage ovarian cancer (FIGO Stage IIIC and IV). J Surg Oncol 107(2):195–200PubMedCrossRef
5.
Menczer J, Usviatzov I, Ben-Shem E, Golan A, Levy T (2011) Neoadjuvant chemotherapy in ovarian, primary peritoneal and tubal carcinoma: can imaging results prior to interval debulking predict survival? J Gynecol Oncol 22(3):183–187PubMedCentralPubMedCrossRef
6.
Bristow RE, Chi DS (2006) Platinum-based neoadjuvant chemotherapy and interval surgical cytoreduction for advanced ovarian cancer: a meta-analysis. Gynecol Oncol 103:1070–1076PubMedCrossRef
7.
Raspaglio G, Fillipetti F, Prislei F, Penci R, De Maria I, Cicchillitti K, Mozzetti S, Scambia G, Ferlini C (2008) Hypoxia induces class III beta-tubulin gene expression by HIF-1 alpha binding to its 3′ flanking region. Gene 409(1–2):100–108PubMedCrossRef
8.
Magnani M, Ortuso F, Soro S, Alcaro S, Tramontano A, Botta M (2006) The β-I/β-III- tubulin isoforms and their complexes with antimitotic agent: docking and molecular dynamics studies. FEBS J 273:3301–3310PubMedCrossRef
9.
De Donato M, Mariani M, Petrella L, Martinelli E, Zannoni GF, Vellone V, Ferrandina G, Shahabi S, Scambia G, Ferlini C (2012) Class III β-tubulin and the cytoskeletal gateway for drug resistance in ovarian cancer. J Cell Physiol 227:1034–1041PubMedCrossRef
10.
Ferlini C, Raspaglio G, Cicchillitti L, Mozzetti S, Prislei S, Bartollino S, Scambia G (2007) Looking at drug resistance mechanisms for microtubule interacting drugs: does TUBB3 work? Curr Cancer Drug Targets 7(8):704–712PubMedCrossRef
11.
Sève P, Dumontet C, Reiman T (2010) Role of tubulin-β-III in predicting chemoresistance in non-small cell lung cancer. Lung Cancer 67(2):136–143PubMedCrossRef
12.
Tommasi S, Mangia A, Lacalamita R, Bellizzi A, Fedele V, Chiriatti A, Thomssen C, Kendzierski N, Latorre A, Lorusso V, Schittulli F, Zito F, Kavallaris M, Paradiso A (2007) Cytoskeleton and paclitaxel sensitivity in breast cancer: the role of β-tubulins. Int J Cancer 120:2078–2085PubMedCrossRef
13.
Mariani M, Zannoni G, Sioletic S, Sieber S, Martino C, Martinelli E, Coco C, Scambia G, Shahabi S, Ferlini C (2012) Gender influences the Class III and V beta-tubulin ability to predict poor outcome in colorectal cancer. Clin Cancer Res 18(10):2964–2975PubMedCrossRef
14.
Sève P, Reiman T, Lai R, Hanson J, Santos C, Johnson L, Dabbagh L, Sawyer M, Dumontet C, Mackey JR (2007) Class III β-tubulin is a marker of paclitaxel resistance in carcinomas of unknown primary site. Cancer Chemother Pharmacol 60:27–34PubMedCrossRef
15.
Bollag DM, McQueney PA, Zhu J, Hensens O, Koupal L, Liesch J, Goetz M, Lazarides E, Woods CM (1995) Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action. Cancer Res 55:2325–2333PubMed
16.
Tavassoli FA, Devilee P (2003) World Health Organization: Tumours of the Breast and Female Genital Organs. IARC Press, Lyon
17.
El-Sahwi K, Bellone S, Cocco E, Cargnelutti M, Casagrande F, Bellone M, Abu-Khalaf M, Buza N, Tavassoli FA, Hui P, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Pecorelli S, Santin AD (2010) In vitro activity of pertuzumab in combination with trastuzumab in uterine serous papillary adenocarcinoma. Br J Cancer 102(1):134–143PubMedCentralPubMedCrossRef
18.
Tassi RA, Bignotti E, Rossi E (2007) Overexpression of mammaglobin B in epithelial ovarian carcinomas. Gynecol Oncol 105:578–585PubMedCrossRef
19.
Carrara L, Guzzo F, Roque DM, Bellone S, Cocco E, Sartori E, Pecorelli S, Schwartz PE, Rutherford TJ, Santin AD (2012) Differential in vitro sensitivity to patupilone versus paclitaxel in uterine and ovarian carcinosarcoma cell lines is linked to tubulin-beta-III expression. Gynecol Oncol 125(1):231–236PubMedCentralPubMedCrossRef
20.
Mozzetti S, Ferlini C, Concolino P, Filippetti F, Raspaglio G, Prislei S, Gallo D, Martinelli E, Ranelletti F, Ferrandina G, Scambia G (2005) Class III β-tubulin overexpression is a prominent mechanism of paclitaxel resistance in ovarian cancer patients. Clin Cancer Res 11:298–305PubMed
21.
Roque DM, Bellone S, English DP, Buza N, Cocco E, Gasparrini S, Bortolomai I, Ratner E, Silasi DA, Azodi M, Rutherford TJ, Schwartz PE, Santin AD (2013) Tubulin-β-III overexpression by uterine serous carcinomas is a marker for poor overall survival after platinum/taxane chemotherapy and sensitivity to epothilones. Cancer. doi:10.​1002/​cncr.​28017 PubMed
22.
Roque DM, Bellone S, Buza N, Romani C, Cocco E, Bignotti E, Ravaggi A, Rutherford TJ, Schwartz PE, Pecorelli S, Santin AD (2013) Class III β-tubulin overexpression in ovarian clear cell and serous carcinoma as a marker for poor overall survival after platinum/taxane chemotherapy and sensitivity to patupilone. Am J Obstet Gynecol. doi:10.​1016/​ajog.​2013.​04.​017 PubMed
23.
Umezu T, Shibata K, Kajiyama H, Terauchi M, Ino K, Nawa A, Kikkawa F (2008) Taxol resistance among the different histological subtypes of ovarian cancer may be associated with the expression of class III beta-tubulin. Int J Gynecol Pathol 27(2):207–212PubMed
24.
Tian Q, Stepaniants SB, Mao M, Weng L, Feetham MC, Doyle MJ, Yi EC, Dai H, Thorsson V, Eng J, Goodlett D, Berger JP, Gunter B, Linseley PS, Stoughton RB, Aebersold R, Collins SJ, Hanlon WA, Hood LE (2004) Integrated genomic and proteomic analyses of gene expression in mammalian cells. Mol Cell Proteomics 3:960–969PubMedCrossRef
25.
Vergote I, De Wever I, Tjalma W, Van Gramberen M, Decloedt J, van Dam P (1998) Neoadjuvant chemotherapy or primary debulking surgery in advanced ovarian carcinoma: a retrospective analysis of 285 patients. Gynecol Oncol 71:431–436PubMedCrossRef
26.
Zivanovic O, Eisenhauer EL, Zhou Q, Iasonos A, Sabbatini P, Sonoda Y, Abu-Rustum NR, Barakat RR, Chi DS (2008) The impact of bulky upper abdominal disease cephalad to the greater omentum on surgical outcome for stage IIIC epithelial ovarian, fallopian tube, and primary peritoneal cancer. Gynecol Oncol 108:287–292PubMedCrossRef
27.
Aletti GD, Dowdy SC, Podratz KC, Cliby WA (2006) Surgical treatment of diaphragm disease correlates with improved survival in optimally debulked advanced stage ovarian cancer. Gynecol Oncol 100:283–287PubMedCrossRef
28.
Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ (2002) Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 20:1248–1259PubMedCrossRef
29.
Chi DS, Eisenhauer EL, Lang J, Huh J, Haddad L, Abu-Rustum NR, Sonoda Y, Levine DA, Hensley M, Barakat RR (2006) What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)? Gynecol Oncol 103:559–564PubMedCrossRef
30.
du Bois A, Reuss A, Pujade-Lauraine E, Harter P, Ray-Coquard I, Pfisterer J (2009) Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multi- center trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d’Investigateurs Nationaux Pour les Etudes des Cancers de l’Ovaire (GINECO). Cancer 115:1234–1244PubMedCrossRef
31.
Kavallaris M, Kuo DY, Burkhart CA, Regl DL, Norris MD, Haber M, Horwitz SB (1997) Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific beta-tubulin isotypes. J Clin Invest 100(5):1282–1293PubMedCentralPubMedCrossRef
32.
Mozzetti S, Ferlini C, Concolino P, Filippetti, Raspaglio G, Prislei S, Gallo D, Martinelli E, Ranelletti FO, Ferrandina G, Scambia G (2005) Class III beta-tubulin overexpression is a prominent mechanism of paclitaxel resistance in ovarian cancer patients. Clin Cancer Res 11(1):298–305PubMed
33.
Mariani M, Shahabi S, Sieber S, Scambia G, Ferlini C (2011) Class III β-tubulin (TUBB3): more than a biomarker in solid tumors? Curr Mol Med 11:726–731PubMedCrossRef
34.
Thongwatchara P, Promwikorn W, Srisomsap C, Chokchaichamnankit D, Boonyaphiphat P, Thongsuksai P (2011) Differential protein expression in primary breast cancer and match axillary node metastasis. Oncol Rep 26(1):185–189PubMed
35.
Kang CH, Jang BG, Kim D-W, Chung DH, Kim YT, Jheon S, Sung S-W, Hyun J (2009) Differences in the expression profiles of excision repair cross complementation group 1, X-ray repair crosscomplementation group 1, and β-III tubulin between primary non-small cell lung cancer and metastatic lymph nodes and the significance in mid-term survival. J Thoracic Oncol 4(11):1307–1312CrossRef
36.
van Diest PJ, van Dam P, Henzen-Logmans SC, Berns E, van der Burg ME, Green J, Vergote I (1997) A scoring system for immunohistochemical staining: concensus report of the task force for basic research of the EORTC-GCCG. J Clin Pathol 50:801–804PubMedCrossRef
37.
Ferrandina G, Zannoni GF, Martinelli E, Paglia A, Gallotta V, Mozzetti S, Scambia G, Ferlini C (2006) Class III β-Tubulin overexpression is a marker of poor clinical outcome in advanced ovarian cancer patients. Clin Cancer Res 12:2774–2789PubMedCrossRef
38.
Chefetz I, AlveroAB Holberg JC, Lebowitz N, Craveiro V, Yang-Hatwich Y, Yin G, Squillace L, Sorteras M, Aldo P, Mor G (2013) TLR2 enhances ovarian cancer stem cell self-renewal and promotes tumor repair and recurrence. Cell Cycle 12(3):511–521PubMedCrossRef
39.
Ferlini C, Raspaglio G, Mozzetti S, Cicchillitti L, Filippetti F, Gallo D, Fattorusso C, Campiani G, Scambia G (2005) The seco-taxane IDN5390 is able to target class III β-tubulin and to overcome paclitaxel resistance. Cancer Res 65:2397–2405PubMedCrossRef
40.
Ranganathan S, Benetatos CA, Colarusso PJ, Dexter DW, Hudes GR (1998) Altered β-tubulin isotype expression in paclitaxel-resistant human prostate carcinoma cells. Br J Cancer 77:562–566PubMedCentralPubMedCrossRef
41.
Del Carmen MG, Birrer M, Shorge JO (2012) Uterine papillary serous cancer: a review of the literature. Gynecol Oncol 127:652–661
42.
Moller KA, Gehrig PA, Van Le L, Secord AA, Schorge J (2004) The role of optimal debulking in advanced stage serous carcinoma of the uterus. Gynecol Oncol 94(1):170–174PubMedCrossRef
43.
Resnik E, Taxy JB (1996) Neoadjuvant chemotherapy in uterine papillary serous carcinoma. Gynecol Oncol 62(1):123–127PubMedCrossRef
44.
Le TD, Yamada SD, Rutgers JL, DiSaia PJ (1999) Complete response of a stage IV uterine papillary serous carcinoma to neoadjuvant chemotherapy with Taxol and carboplatin. Gynecol Oncol 73(3):461–463PubMedCrossRef
45.
Gan PP, Pasquier E, Kavallaris M (2007) Class III tubulin mediates sensitivity to chemotherapeutic drugs in non-small cell lung cancer. Cancer Res 67:9356–9936PubMedCrossRef
46.
Gan PP, McCarroll JA, Byrne FL, Garner J, Kavallaris M (2011) Specific-b-III tubulin isotypes can functionally enhance or diminish epothilone B sensitivity in non-small cell lung cancer cells. PLoS One 6(6):e21717PubMedCentralPubMedCrossRef
47.
Pusztai L (2007) Markers predicting clinical benefit in breast cancer from microtubule-targeting agents. Ann Oncol Suppl 12:xii15–20
48.
De Geest K, Blessing JA, Morris RT, Monk BJ, Zweizig SL, Matei D, Muller CY, Richards WE (2009) Phase II clinical trial of ixabepilone in patients with recurrent or persistent platinum- and taxane-resistant ovarian or primary peritoneal cancer: a gynecologic oncology group study. J Clin Oncol 28:149–153PubMedCrossRef
49.
Dizon DS, Blessing JA, McMeekin DS, Sharma SK, DiSilvestro P, Alvarez RD (2009) Phase II trial of ixabepilone as second-line treatment in advanced endometrial cancer: gynecologic Oncology Group Trial 129-P. J Clin Oncol 27:3104–3108PubMedCrossRef
50.
51.
Vansteenkiste J, Lara PN Jr, Le Chevalier T, Breton JL, Bonomi P, Sandler AB, Socinski MA, Delbaldo C, McHenry B, Lebwohl D, Peck R, Edelman MJ (2007) Phase II clinical trial of the epothilone B analog, ixabepilone, in patients with non-small cell lung caner whose tumors have failed first-line platinum-based chemotherapy. J Clin Oncol 25(23):3448–3455PubMedCrossRef
52.
Spigel DR, Anthony Greco F, Waterhouse DM, Shipley DL, Zubkus JD, Bury MJ, Webb CD, Hart LL, Gian VG, Infante JR, Burris HA 3rd, Hainsworth JD (2012) Phase II trial of ixabepilone and carboplatin with or without bevacizumab in patients with previously untreated advanced non-small cell lung cancer. Lung Cancer 78(1):70–75PubMedCrossRef
53.
McMeekin S, Patel R, Verschraegen C, Celano P, Burke J 2nd, Plaxe S, Ghatage P, Giurescu M, Stredder C, ang Y, Schmelter T (2012) Phase I/II study of sagopilone (ZK-EPO) plus carboplatin in women with recurrent platinum-sensitive ovarian cancer. Br J Cancer 106(1):70–76PubMedCentralPubMedCrossRef
Metadata
Title
Class III β-tubulin overexpression within the tumor microenvironment is a prognostic biomarker for poor overall survival in ovarian cancer patients treated with neoadjuvant carboplatin/paclitaxel
Authors
Dana M. Roque
Natalia Buza
Michelle Glasgow
Stefania Bellone
Ileana Bortolomai
Sara Gasparrini
Emiliano Cocco
Elena Ratner
Dan-Arin Silasi
Masoud Azodi
Thomas J. Rutherford
Peter E. Schwartz
Alessandro D. Santin
Publication date
01-01-2014
Publisher
Springer Netherlands
Published in
Clinical & Experimental Metastasis / Issue 1/2014
Print ISSN: 0262-0898
Electronic ISSN: 1573-7276
DOI
https://doi.org/10.1007/s10585-013-9614-5

Other articles of this Issue 1/2014

Clinical & Experimental Metastasis 1/2014 Go to the issue

Review Paper

The current status of tailor-made medicine with molecular biomarkers for patients with clear cell renal cell carcinoma

Research Paper

Pre-treatment of mice with tumor-conditioned media accelerates metastasis to lymph nodes and lungs: a new spontaneous breast cancer metastasis model

Research Paper

Prolonged survival following aggressive treatment for metastatic breast cancer in the spine

Research Paper

Role of L1 cell adhesion molecule (L1CAM) in the metastatic cascade: promotion of dissemination, colonization, and metastatic growth

Research Paper

Melanoma brain metastases: the impact of nodal disease

Review

Metastasis of ovarian cancer is mediated by kallikrein related peptidases
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits